An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients

Chen J. Lin, Fang J. Sun, Chun K. Fang, Hong W. Chen, Yuen Liang Lai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study compared the efficacy between haloperidol and olanzapine to treat the delirious syndromes in the palliative and hospice center cancer patients. Patients those received hospice and palliative care, with an advanced cancer, and met the DSM-IV criteria for delirium were recruited. They were administered the DRS-c and CGI-S at the time point of T0,T1,T2,T3 during 1 week. 16 patients (M:F=9:7; mean age ± SD=61.13 ± 16.5) in olanzapine group and 14 patients (M:F=4:10; mean age ± SD=68 ± 12.14) in haloperidol group were recruited. In both groups there was significant difference in scores of DRS-c and CGI-S across time periods (haloperidol group: DRS-c: at T1, p=0.008; at T2, p=0.044; at T3, p=0.043 and CGI-S: at T1, p=0.012; olanzapine group: DRS-c: at T3, p=0.042 and CGI-S: at T1, p=0.040). However, comparison of the scores of DRS-c and CGI-S across time periods between two groups showed no statistical difference. The results showed that the delirium improved in both groups but no statistic difference comparing both groups. Therefore, olanzapine might be a useful alternative to haloperidol in the treatment of delirium in advanced cancer patients.

Original languageEnglish
Pages (from-to)346-354
Number of pages9
JournalJournal of Internal Medicine of Taiwan
Volume19
Issue number4
Publication statusPublished - Aug 2008

Keywords

  • Advanced cancer patients
  • Delirium
  • Haloperidol
  • Olanzapine
  • Palliative and hospice care

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients'. Together they form a unique fingerprint.

Cite this